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Abstract
Background: Abdominal aortic aneurysm (AAA) is characterized by increased aortic vessel wall diameter (.1.5 times
normal) and loss of parallelism. This disease is responsible for 1–4% mortality occurring on rupture in males older than 65
years. Due to its asymptomatic nature, proteomic techniques were used to search for diagnostic biomarkers that might
allow surgical intervention under nonlife threatening conditions.
Methodology/Principal Findings: Pooled human plasma samples of 17 AAA and 17 control patients were depleted of the
most abundant proteins and compared using a data-independent shotgun proteomic strategy, Precursor Acquisition
Independent From Ion Count (PAcIFIC), combined with spectral counting and isobaric tandem mass tags. Both quantitative
methods collectively identified 80 proteins as statistically differentially abundant between AAA and control patients. Among
differentially abundant proteins, a subgroup of 19 was selected according to Gene Ontology classification and implication in
AAA for verification by Western blot (WB) in the same 34 individual plasma samples that comprised the pools. From the 19
proteins, 12 were detected by WB. Five of them were verified to be differentially up-regulated in individual plasma of AAA
patients: adiponectin, extracellular superoxide dismutase, protein AMBP, kallistatin and carboxypeptidase B2.
Conclusions/Significance: Plasma depletion of high abundance proteins combined with quantitative PAcIFIC analysis
offered an efficient and sensitive tool for the screening of new potential biomarkers of AAA. However, WB analysis to verify
the 19 PAcIFIC identified proteins of interest proved inconclusive save for five proteins. We discuss these five in terms of
their potential relevance as biological markers for use in AAA screening of population at risk.
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Introduction
Abdominal aortic aneurysm (AAA) is one of the leading causes
of death in industrialized countries where a growing percentage of
the population is over 65 years of age [1]. AAA is a vascular
pathology characterized by an increase of aorta diameter to at
least 1.5 times the diameter of a standard reference or $30 mm of
infrarenal aorta diameter, and a loss of parallelism of the aortic
wall at the infrarenal region. Known risk factors for AAA are
advanced age, male gender, cigarette smoking, hypertension,
genetic susceptibility and the presence of another atherosclerotic
localization [2]. Hence AAA primarily affects elderly males at a
prevalence of 5% with ruptures being responsible for 1–4% of the
total mortality in males older than 65 years. Moreover, mortality
occurs in 65–75% of patients before they arrive at hospital [3].
This high mortality is largely due to the fact that the vast majority
of AAA patients are asymptomatic and diagnosis is normally not
possible prior to rupture [4].
Until now, most proteomic studies attempting to define AAA
biological markers were performed either in AAA tissue samples
[5], or in conditioned media containing proteins released from
AAA tissue [6,7], considering that pathological mechanisms take
place in a primary aortic blood vessel and that biological changes
in aortic tissue will be reflected in those released proteins. Indeed,
only one discovery proteomic study has been reported on AAA
serum samples [8], which led to the identification of three highly
abundant proteins, but none were deemed plausible potential
biomarkers of aneurismal disease. Recently, we performed a
combined transcriptomic and proteomic study in macrophage
extracts that was verified by antibody protein array in the same
cell extracts and in plasma of AAA patients [9]. All these
proteomic studies for AAA biomarker discovery used profiling
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time of flight mass spectrometry (MS) or 2-dimensional gel
electrophoresis to compare protein abundance between two or
more groups of samples.
Our most recent work presented here used a new data-
independent (DIA) shotgun proteomics method, PAcIFIC [10,11]
for the quantitative analysis of plasma samples that were depleted
of the 14 most abundant proteins. In order to quantify the larger
number of proteins, two different quantitative methods were
applied: spectral count and TMT isobaric labeling. The
quantitative PAcIFIC technology proved to be a powerful tool
for the discovery of proteins differentially abundant between
pooled plasma samples from AAA and control patients. We
present here the results of this study, which is the first high
throughput quantitative proteomic study comparing plasma
proteomes of patients with and without AAA. This study was
performed with the following objectives to: 1) identify and evaluate
potential biological markers for AAA screening, which will ensure
early diagnosis and subsequent early treatment prior to rupture
events which have very high mortality, and 2) provide a better
understanding of the pathophysiological mechanisms involved in
the evolution of AAA. Our quantitative proteomic strategy
allowed the identification of five potential biomarkers of AAA,
three of which are proteins involved in the regulation of the
kallikrein-kinin system, which others have suggested may play a
role in the evolution of AAA.
Results
In order to find potential biological markers of AAA, our
proteomic strategy (Fig. 1) applied a quantitative version of the
DIA PAcIFIC method to identify differences in protein abundance
between two plasma pools of 17 AAA and 17 control patients each
previously depleted of the 14 most abundant proteins.
Clinical population
There was no statistically significant difference between the
baseline characteristics of AAA and control patients selected in this
study, except for the presence or absence of AAA (Table 1).
MS protein analysis of pooled plasma samples
Qualitative analysis from the label-free experiment. Con-
sidering only peptide identifications with probability scores $0.9
(FDR,1%), duplicate PAcIFIC MS analysis identified
approximately one thousand proteins per sample. In the control
pooled plasma sample, 328 proteins were identified with at least two
peptides (i.e. multiple hit identifications), whereas 667 proteins were
identified with only one peptide (single hit identifications). In the
AAA pooled plasma sample, 311 proteins were identified as multiple
hits while 687 proteins were identified as single hits. Using only the
list of proteins identified with multiple unique peptides PAcIFIC
analysis provided an apparent dynamic range of detection of
4.5E+06. For example, using representative identified proteins with
known plasma concentrations we detected proteins of the following
concentrations: 72 kDa type IV collagenase (8.8E+03 pg/mL), L-
selectin (1.7E+04 pg/mL), beta-2-microglobulin (1.1E+06 pg/mL),
apolipoprotein E (3.4E+07 pg/mL), ceruloplasmin (2.1E+08 pg/
mL), alpha-2-macroglobulin (1.4E+09 pg/mL) and albumin
(4.0E+10 pg/mL).
Biomarker discovery in pooled plasma samples. Quan-
titative analysis of plasma samples from control and AAA patients
performed by PAcIFIC using the label-free spectral counting and
the isotopic dilution TMT method are presented in Supporting
information S1. Only proteins identified by multiple unique
peptides were considered. Duplicate normalized spectral counts
were used to calculate statistically significant differences in protein
ratios (p-value,0.05) between AAA and control samples. Of 308
proteins quantified, 53 proteins appeared to be significantly
differentially abundant between AAA and control pooled plasma
samples. From these, 18 were up-regulated and 35 down-regulated
in AAA pooled plasma samples compared to controls.
The total number of proteins identified in the TMT-duplex
experiment was 788, and reporter ion intensity values of 146
proteins could be used to calculate AAA to control protein ratios
and 40 proteins appeared to be differentially abundant (p-
value,0.05) between AAA and controls. From these, 30 were
up-regulated and 10 down-regulated in AAA pooled plasma
samples compared to controls.
The twoquantitative analyses determined 80 proteins exhibiting a
statistically significant change in abundance, of which eight were in
common to both methods: complement C1s subcomponent, alpha-
2-antiplasmin, and Complement factor H-related protein 1,
ceruloplasmin, complement C5, apolipoprotein B-100, inter-alpha-
trypsin inhibitor heavy chain H3, inter-alpha-trypsin inhibitor heavy
chain H4 . Finally, the last five proteins showed the same change in
abundance by both TMT labeling and spectral counting analysis.
Verification of differentially regulated proteins by
Western blot
Selection of putative biomarker proteins. The 80 proteins
whose change in abundance was found to be statistically significant
were classified by GO analysis. From this analysis, 19 proteins
were identified in the following three categories as most likely
related to putative AAA biological mechanisms: 1) vascular
remodeling (vinculin, alpha-actinin-1, talin-1, gelsolin, adenylyl
cyclase-associated protein 1 (CAP1), profilin-1, and filamin-A), 2)
intraluminal thrombus formation and coagulation (protein AMBP,
extracellular superoxide dismutase, carboxypeptidase N catalytic
chain (CPN1), carboxypeptidase B2, platelet basic protein, alpha-
2-antiplasmin, pleckstrin, corticosteroid binding globulin, heparin
cofactor 2, and kallistatin), and 3) inflammatory response
(lysozyme C, and adiponectin). Most of these proteins had not
previously been directly identified in plasma of AAA patient and so
they were followed in individual patient plasma by WB analysis
(Supporting information S1).
Biomarker verification in individual patient plasma. Of
the 19 proteins chosen, only gelsolin, adiponectin, extracellular
superoxide dismutase, corticosteroid-binding globulin, kallistatin,
and carboxypeptidase B2 were detected and quantified by WB
analysis in crude plasma (Fig. 2) of the 34 individual patients’
plasma. While gelsolin and corticosteroid-binding globulin did not
show any significant difference of protein abundance between AAA
and control patients, the remainder did. Specifically, adiponectin,
kallistatin, extracellular superoxide dismutase, and carboxypeptidase
B2 were detected as being abundant at significantly increased levels
in AAA compared to control plasma samples.
CAP1, pleckstrin, vinculin, CPN1, heparin cofactor 2, and
protein AMBP were detected and quantified after removal of the
14 most abundant proteins by immunodepletion (Fig. 2). Only
AMBP appeared to be significantly up-regulated in AAA
compared to control plasma samples, as shown by MS
quantification. AAA to control ratios of both MS and WB
quantification of selected proteins are presented in Table 2.
Discussion
The aim of the present study was to identify and confirm
potential biological markers for AAA screening and to provide a
AAA Plasma Biomarkers Detected by PAcIFIC MS
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involved in the presence of AAA. To accomplish these goals, we
used quantitative DIA PAcIFIC analysis to discover proteins
differentially abundant between pooled plasma samples from 17
AAA and 17 control patients. GO analysis was performed on the
80 proteins identified as putative biomarkers to further refine the
set to be examined by WB analysis on individual patient plasma
samples.
The 17 AAA and 17 control patients were selected from 265
recruited in the CORONA study [12]. This sub-population had a
well-defined phenotype and the baseline characteristics of AAA
and control patients did not present any significant differences
except aneurismal pathology, i.e. they seemed to have the same
cardiovascular risk factors. Thus, the main interest here was to
identify potential biomarkers that discriminate patients with very
similar phenotypes. In order to do so WB testing of the potential
biomarkers was performed on the same population rather than
healthy patients as controls.
To increase detectable proteomic dynamic range, the 14 most
abundant proteins were immunodepleted prior to PAcIFIC
analysis. The plasma proteome is arguably the most complex
human-derived proteome, with a dynamic range of protein
Figure 1. Workflow for the proteomic analysis of protein plasma samples. 17 plasma samples of each group were analyzed by two different
quantitative strategies after DIA PAcIFIC MS: (A) spectral count, and (B) tandem mass tag isobaric labeling. After selection, only proteins that were
verified by Western Blot were considered as potential biological markers for AAA. ID: identification.
doi:10.1371/journal.pone.0028698.g001
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normal plasma 22 proteins represent 99% of total protein content
[14]. Thus, the challenging analysis of the remaining 1%, known
as ‘‘deep proteome’’, which includes thousands of different
proteins [15], involves a mandatory step of depletion of major
proteins before sample analysis. A recent study [16] showed that
shotgun proteomic analysis of plasma depleted of these most
abundant proteins is highly reproducible. Qualitative analysis of
pooled plasma samples by PAcIFIC identified proteins (multiple
unique peptide hits) over a dynamic range of 4.5E+6 without any
previous fractionation of the sample. This outcome is possible
because the DIA PAcIFIC analysis circumvents the dynamic range
limitations inherent to data-dependent MS based proteomic
methods [17]. Furthermore, the DIA PAcIFIC method is
compatible with two quantitative methods: spectral counting and
TMTs, the latter of which allows samples to be multiplexed [11].
Thus, we have shown, as have others [10,18], the superiority of
DIA methods to extend detectable proteomic dynamic range. In
our study, and taking only multiple hit protein identifications, we
observed that spectral counting has a dynamic range that is one
order of magnitude higher than the TMT isobaric labeling. Hence
spectral counting is better for quantification in a broader range of
protein concentrations but worse for multiplexing. Quantitative
PAcIFIC analysis, using both a label-free spectral count approach
and an isotopic labeling multiplexed TMT approach, produced 80
differentially abundant proteins between AAA and control pooled
plasma samples. These two approaches were complementary,
identifying eight overlapping proteins with significant differences
in abundance. This low number of proteins could be due to sample
processing for the TMT isobaric tagging method that results in loss
of protein or from complexities related to chemical reactions
which never yield 100% efficiency and in so doing exacerbate the
issue of sample complexity.
GO classification of differentially abundant proteins was
performed in order to select a representative protein set for
verification by WB analysis. Nineteen proteins out of 80
potentially involved in aneurismal disease were selected for testing
in individual patient samples. This technique also made feasible
the analysis of individual plasma samples from the 34 patients used
for making pools for the discovery proteomic phase of the study.
Table 1. Baseline characteristics of the CORONA population used for the proteomic analysis.
Characteristics Controls AAA Exact p-value
(n=17) (n=17)
Age (years), median value [25
th to 75
th percentile range] 63 [56–71 61 |57–68] 0.75
Gender, n (% male) 17 (100) 17 (100) ND
BMI (kg/m
2), median value[25
th to 75
th percentile range] 26.2 [25–27.8] 27.7 [24.1–29.9] 0.28
Cardiovascular risk factors, n (%)
Type 2 diabetes 5 (29.4) 6 (35.3) 1
Arterial hypertension 9 (52.9) 10 (58.8) 1
Dyslipidemia 10 (58.8) 12 (70.6) 0.72
Smoking (past or current) 13 (76.5 16 (94.1) 0.33
Positive family history for CVD 5 (29.4) 8 (47.1) 0.48
Personal history of CAD, n (%)
Unstable angina pectoris 4 (23.5) 1 (5.9) 0.33
Stable angina pectoris 5 (29.4) 5 (29.4) ND
Peripheral arterial disease 3 (17.6) 6 (35.3) 0.43
Stroke 1 (5.9) 2 (11.8) 1
Previous myocardial infarction 7 (41.2) 4 (23.5) 0.47
Carotid artery stenosis 5 (29.4) 4 (23.5) 0.69
1- or 2-coronary vessel disease 2 (11.8) 5 (29.4) 0.40
3- or 4-coronary vessel disease 15 (88.2) 12 (70.6) 0.40
Major medications at time of inclusion, n (%)
Aspirin 15 (88.2) 13 (76.47) 0.66
Beta-blockers 13 (76.5) 12 (70.6) 1
ACE inhibitors 4 (23.5) 8 (47.1) 0.28
Calcium antagonists 6 (35.3) 3 (17.6) 0.44
Statins 16 (94.1) 12 (70.6) 0.17
Presence of other arterial aneurisms, n (%)
Iliac aneurismal extension 0(0) 4 (23.5) 0.10
Femoral arterial aneurism 0(0) 1 (5.9) 1
Popliteal arterial aneurism 0(0) 4 (23.5) 0.10
AAA: abdominal aortic aneurysm, ACE: angiotensin converting enzyme, BMI: body mass index, CAD: coronary artery disease, CVD: cardiovascular diseases, ND: no
difference between values of both groups of patients.
doi:10.1371/journal.pone.0028698.t001
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method that is similar to the clinical assays that might eventually
be used to diagnose AAA from control patients. However, here
we note that WB analysis was less sensitive than PAcIFIC analysis
as judged by detection of only 12 of 19 selected proteins. Indeed,
as others have noted, verification of quantitative MS results
during biomarker discovery by existing antibody-based assays
represents a serious limitation [19]. This may be accomplished by
multiple reaction monitoring [20–22], but this is not completely
satisfying in that ideally one would like to have an orthogonal
method for verification. Despite limitations in sensitivity com-
pared to shotgun proteomics, targeted WB analysis offered
supplementary biochemical information of analyzed proteins
such as molecular weight and presence of in vivo protein
fragments. This was the case for adiponectin and kallistatin,
where WB showed two bands that could be explained by the
presence of a signal peptide at the N-terminal part of these
proteins with molecular masses of 1886 Da and 2203 Da,
respectively. These peptides were not observed in MS experi-
ments possibly due to the absence of lysines and arginines until
position 33 (for adiponectin) and 50 (for kallistatin) of the entire
proteins (Supporting information S2)
Of the 12 proteins detected by WB analysis, five appeared to be
differentially up-regulated in plasma samples of AAA compared to
control patients: adiponectin, extracellular superoxide dismutase,
carboxypeptidase B2, kallistatin, and protein AMBP. None of
these five proteins have been previously proposed as potential
biological markers for AAA diagnosis [23–25]. Since only two of
the 17 AAA patients used for the present study had infrarenal
aortic diameter .50 mm (data not shown), our results may be
interpreted as evidence that the five WB verified proteins should
be considered as potential biomarkers for early diagnosis of AAA.
Of the verified proteins, only kallistatin had a AAA to control ratio
by WB analysis that was discordant with the MS result. Indeed,
kallistatin appeared to be up-regulated in AAA plasma samples
because the trend was observed across all 34 patients by WB
whereas the MS result was from a pool, thus highlighting the need
for such follow-up experiment to verify MS-based hypotheses.
Verification of the other seven proteins detected and quantified
probably failed because of inter-individual variability among the
human samples. For this subset of proteins, these results could be
indeed interpreted as even though the inter-individual variability
of humans affects the pooling of samples, our study succeeded in
producing near to 42% of true positives.
Figure 2. Proteins abundance in individual plasma samples from AAA and control patients. Data of all patients tested is represented in a
box plot but only Western blot of three representative samples of each group are presented. The position of Mr value for each protein is indicated.
*p ,0.05; { p,0.01. n=number of patients in each group; A.U.: arbitrary units; U: upper; L: lower.
doi:10.1371/journal.pone.0028698.g002
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processes (Supporting information S1). Adiponectin has
cytokine activity and its level in human serum was already
described to be increased in early AAA patients (diame-
ter,40 mm) compared to controls [26]. Extracellular superoxide
dismutase is involved in superoxide metabolic processes to protect
the extracellular space from ROS. It is well known that oxidative
stress contributes importantly to the development of AAA [27–29].
Carboxypeptidase B2 is an enzyme with metallocarboxypeptidase
activity involved in proteolysis. Protein AMBP gives rise, by
proteolytic cleavage, to two different proteins (Supporting
information S3): alpha-1 microglobulin, a lipocalin whose
biological functions are not known [30], and bikunin, that, as
well as kallistatin, has serine-type endopeptidase inhibitor activity.
Moreover, kallistatin was also described as a potent vasodilator
[31], consistently with increased concentration of this protein in
plasma samples of AAA patients. Importantly, bikunin, i.e. one of
the proteolytic products of protein AMBP, together with kallistatin
and carboxypeptidase B2 are proteins involved in the regulation of
the kallikrein-kinin system (Fig. 3). On one hand, the specific
inactivation of the proteolytic activity of tissue-kallikrein and
plasma-kallikrein can be produced by both kallistatin [32] and
bikunin [33]. On the other hand, carboxypeptidase B2 was
demonstrated to be responsible for the hydrolysis of bradykinin
[34]. Thus, it seems that an increase of kallistatin and bikunin
levels may lead to a decrease of active kinins. In the same way, an
increase of carboxypeptidase B2 levels may generate an increase
on kinin degradation for their subsequent inactivation. Interest-
ingly, it has been demonstrated that kininogen deficiency promotes
the development of AAA in kininogen-deficient Brown Norway
rats after feeding with a high-fat (atherogenic) diet [35]. Therefore,
concerning pathophysiological mechanisms involved in AAA,
these results suggest a relationship between decreased levels of
active kinins and the presence of AAA.
In conclusion, the present study showed that the combination of
plasma depletion of high abundance proteins with DIA PAcIFIC
analysis offered a useful tool for the screening of new potential
biomarkers of AAA. WB analysis confirmed five PAcIFIC
identified proteins as potential biomarkers for early AAA diagnosis
(i.e. adiponectin, extracellular superoxide dismutase, kallistatin,
carboxypeptidase B2, and protein AMBP). The latter three
proteins are known to be involved in the regulation of the
kallikrein-kinin system, which was recently suggested to play a role
in AAA development. Finally, large cohort studies are needed to
validate the application of these five potential biological markers
for the screening of AAA in the population at risk. Also, it will be
Table 2. Comparison between mass spectrometry and western blot analyses.
Mass Spectrometry Western Blot
Protein SC ratio TMT ratio Quantified Ratio
AAA vs. Control AAA vs. Control bands AAA vs. Control p-value
Extracellular superoxide dismutase 4.87 - Unique
1 1.94 0.007
Protein AMBP 1.12 - Unique
2 1.90 0.037
Gelsolin 0.81 - Unique
1 1.08 0.67
Heparin cofactor 2 0.76 - Unique
2 1.02 0.24
Carboxypeptidase N catalytic chain 0.71 - Unique
2 1.00 0.63
Alpha-2 antiplasmin 0.63 1.12 ND NC NC
Vinculin 0.44 - Unique
2 1.45 0.74
Filamin-A 0.40 - ND NC NC
Alpha-actinin-1 0.20 - ND NC NC
Talin-1 0.19 - ND NC NC
Profilin-1 0.16 - ND NC NC
Pleckstrin 0.12 Q - Unique
2 9.04 0.56
Adenylyl cyclase- associated protein 1 0.01 - Unique
2 0.89 0.90
Adiponectin - 1.78 Both
1 2.36 0.0092
Upper
1 1.87 0.033
Lower
1 1.69 0.036
Lysozyme C - 1.39 ND NC NC
Carboxypeptidase B2 - 1.35 Unique
1 1.45 0.0062
Kallistatin - 0.89 Both
1 1.32 0.11
Upper
1 1.20 0.47
Lower
1 1.31 0.046
Corticosteroid-binding globulin - 0.72 Both
1 1.04 0.25
Upper
1 1.00 0.23
Lower
1 1.10 0.74
Platelet basic protein - 0.68 ND NC NC
SC: spectral count. TMT: tandem mass tag. Proteins verified by western blot analysis are indicated in italic. WB on crude plasma samples
1. WB on depleted plasma
samples
2. ND: non detected. NC: non calculated.
doi:10.1371/journal.pone.0028698.t002
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measuring of abundance of these proteins.
Materials and Methods
Clinical population and patients matching for the
proteomic analysis
CORONA clinical protocol included 265 patients with
advanced coronary disease who underwent coronary artery bypass
grafting from 2002 to 2006 in University Regional Hospital
Center of Lille (France). The ethics committee of the Lille
University Hospital Center (France) approved the study, and each
patient provided written informed consent (CP 01/96 of 04/12/
01). Vascular and abdominal echography examination was
performed after surgery to check the quality of bypass and the
presence of AAA by measuring the aorta diameter. At the time of
recruitment, AAA was detected in 17 patients (6.4% of the
population), considering aortic diameter $30 mm or infra- to
supra-renal ratio .1.5. Venous blood samples were obtained from
all patients the day before the surgery.
The 17 AAA patients were paired with 17 controls, according to
their age, gender, tobacco consumption, arterial hypertension,
diabetes and dyslipidemia. Age distributions of plasma samples
from selected control and AAA patients were similar over the time
(data not shown). The biological and clinical data of these 34
patients were analyzed by exact nonparametric inference tests
(StatXact.8 software) and permutation test was used for contin-
uous data. For categorical data, Fisher’s exact test and Pearson’s
Chi-square test were used to analyze binomial and multinomial
data, respectively.
Plasma sample treatment
Plasma samples (EDTA as anticoagulant) were collected within
2 h from centrifugation (1109 g, 15 min at room temperature) of
7.5 mL blood sample. Plasma samples were divided into 300 mL
aliquots and stored at 280uC. They did not undergo more than
two freeze/thaw cycles before processing for proteomic analysis.
A pool of both groups of patients (17 AAA and 17 controls) was
prepared using 50 mL of plasma per patient. Two-hundred mlo f
each pool and 70 mL of individual plasma samples (for WB) were
depleted for the 14 most abundant proteins using Multiple Affinity
Removal System Hu-14 (MARS-14) spin cartridge (Agilent
Technologies, Santa Clara, CA) according to the manufacturer’s
protocol. After depletion, pooled and individual plasma samples
were concentrated in 500 mL of 100 mM ammonium bicarbonate
using spin concentrators (Agilent Technologies, Santa Clara, CA),
and protein concentration was determined by Bradford assay
(Biorad, Hercules, CA).
Urea (6 M final concentration) was added to depleted plasma
pools before reduction with 2.5 mL of 200 mM dithiothreitol at
37uC for 1 h, and alkylation with 11.25 mL of 200 mM
iodoacetamide at 37uC for 1 h in the dark. Samples were then
diluted three times with 100 mM ammonium bicarbonate before
addition of trypsin (enzyme to protein ratio of 1:50). Digestion was
carried out overnight at 37uC. Peptides of digests were desalted on
C18 macrospin columns (The Nest Group, Southborough, MA)
according to the manufacturer’s instructions and stored at 280uC
until PAcIFIC MS analysis was performed.
Peptide labeling and PAcIFIC MS
Each pooled plasma sample was run in duplicate for both
PAcIFIC and quantitative PAcIFIC MS analyses. For PAcIFIC
MS, peptide samples were dried with a vacuum concentrator and
resuspended in 5% acetonitrile, 0.1% formic acid to reach an
estimated peptide concentration of 0.5 mg/mL. HPLC was
performed on a Waters NanoAcquity (Manchester, U.K.) system
using homemade columns and precolumns as previously described
[36]. An estimated amount of 1 mg of plasma peptides was used for
each sample injection. A LTQ XL linear ion trap mass
spectrometer (ThermoFisher, San Jose, CA) was used to perform
PAcIFIC MS analysis as previously described [10]. Briefly, in a
first injection, PAcIFIC acquisition used 15 consecutive collision-
induced dissociation (CID) MS/MS scans of m/z=401.5, 403,
404.5, 406, 407.5, 409, 410.5, 412, 413.5, 415, 416.5, 418, 419.5,
421 and 422.5 with an isolation width set to 2.5 and collision
energy to 35%. In the consecutive range, m/z values from 422.5 to
445 were analyzed, and so on until m/z=1412.5 was reached (45
repeated injections in total).
Tandem mass tag (TMT) duplex approach [37] was used for
quantitative PAcIFIC MS [11]. Peptide mixtures corresponding to
control and AAA pooled plasma were labeled with TMT2-126
and TMT2-127 (ThermoScientific, Rockford, IL) respectively,
according to manufacturer’s protocol. Labeled samples were
combined, dried in a vacuum concentrator and dissolved in 5%
acetonitrile, 0.1% formic acid to reach an estimated peptide
concentration of 0.5 mg/mL. MS and HPLC conditions were the
same as described above. Quantitative PAcIFIC MS analysis was
applied as described above with the following modifications:
between each CID fragmentation scan, a zoomed pulsed-Q
dissociation scan with collision energy set to 35%, activation
Q=0.55, and activation time=0.4 was performed from m/
z=121 to 132 in order to measure the TMT reporter ions.
Data processing and quantification of PAcIFIC MS
For each PAcIFIC or quantitative PAcIFIC replicate, RAW files
were converted to mzXML files (45 files in total) and peak lists
were generated and searched with Sequest against the IPI human
database v3.49 (74017 entries; http://www.ebi.ac.uk/IPI/IPIhu-
man.html). The following settings were used: proteolytic enzyme:
trypsin; number of missed cleavages permitted: 1; precursor
Figure 3. Simplified schematic representation of kallikrein-kinin system regulation. Kininogen is cleaved by kininogenases, such as tissue
kallikrein, to generate active kinins. Kallistatin and bikunin are specific inhibitors of tissue kallikrein. Carboxypeptidases, such as carboxypeptidase B2,
can cleave C-terminal arginine or lysine residues from active kinins, i.e. bradikinin, to inactivate them thereby regulating their activities.
doi:10.1371/journal.pone.0028698.g003
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variable modification: oxidized methionine. Sequest results were
converted to pepXML files and probability assessments of
identified peptides were computed with PeptideProphet (ISB,
Seattle, WA). For all individual searches (45 pepXML files or 1
replicate), peptides with probability scores equal or higher than 0.9
were used (estimated false discovery rate (FDR),1%). PAcIFIC
dynamic range for protein identification was calculated only
considering proteins identified as multiple hits (with at least 2
unique peptides), with FDR,1%, and using known plasma
protein concentration values, described by the HUPO Plasma
Proteome Project [38]. For searches on TMT-labeled samples, the
TMT modification was added as fixed, and the intensities of TMT
reporter ions (m/z=126 and m/z=127) were extracted from raw
data files. Intensity ratios were calculated and normalized to 126-
TMT reporter ion using the program Libra (ISB, Seattle, WA).
For each protein, the ratio was calculated as a mean value of all
intensity ratios of peptides identified. For all searches, when
peptides matched to multiple members of a protein family,
identification is represented by only one name of proteins or
isoforms included in the identified family.
Protein quantifications were calculated only in multiple hit
proteins (with at least 2 unique peptides) and with FDR,1%. For
spectral count analysis [39], number of spectra per protein were
computed with ProteinProphet (ISB, Seattle, WA). Datasets of
MS/MS data with significant identification assignments were
exported into Excel and average spectral counts of duplicates were
calculated and normalized to the sum of all spectra from the
sample with the highest number of spectra, i.e. AAA plasma
sample. In order to avoid missing values when a protein was not
identified in one group (control or AAA), an arbitrary value of 0.1
was summed to the number of spectral counts. Then, G-test was
applied to spectral counts of each protein in every sample in order
to evaluate differences of protein abundance [40]. P-values,0.05
were considered as significant.
Datasets of MS/MS data containing mean values of intensity
ratios of TMT reporter ions were exported into Excel. Then, t-test
was applied to duplicated values of intensity ratios for each protein
in order to evaluate differences of protein abundance. Significant
proteins were considered when p-value,0.05 and fold change
.12%, since variation in technical replicates for isobaric labeling
has been estimated to that value [41,42].
Selection of proteins to be verified
Gene Ontology (GO) annotations of significant differentially
abundant proteins were automatically assigned with the freely
available internet tool Protein Information and Property Explorer
[43]. Assignments were manually filtered according to the
biological implications in the pathology, and validated using the
GO Consortium tool AmiGO Version 1.7 and GO database
release of 2010-07-31 [44]. According to this classification,
proteins to be verified were selected in order to cover the wide
variety of biological processes and molecular functions that the
literature indicates may be involved in AAA biological mecha-
nisms such as 1) vascular remodeling, 2) intraluminal thrombus
formation and coagulation, and 3) inflammatory response. Lastly,
we focused on proteins which had not been previously identified in
plasma of AAA patients.
Western blot analysis
WB analysis was performed on the same 17 AAA and 17 control
individual plasmasamplesthat wereusedfortheproteomicanalysis.
Plasma proteins (depleted or not with human MARS-14) were
diluted with 38 mL of RIPA buffer and separated by SDS-PAGE
(12% acrylamide gels for all proteins except for adiponectin (15%)
and vinculin (6%)). Then, proteins were electrotransferred onto a
0.45 mm Hybond nitrocellulose membrane (GE Healthcare), except
for corticosteroid-binging globulin, AMBP and pleckstrin, for which
a PVDF membrane (Sigma Aldrich) was used. Visual verification of
total protein loads was performed by Ponceau staining of the
membranes. Primary antibodies, that were diluted in 5% w/v non
fat dry milk in TBS-Tween and used at 4uC, overnight, were:
polyclonal rabbit anti human adiponectin (2 mL crude plasma,
1:1000 v/v, Abcam); monoclonal mouse anti human gelsolin (2 mL
crude plasma, 1:5000 v/v, Sigma Aldrich); polyclonal rabbit anti
human corticosteroid-binding globulin (2 mL crude plasma, 1:500
v/v, Proteintech group inc); polyclonal rabbit anti human
extracellular superoxide dismutase [Cu-Zn] (2 mL crude plasma,
1:100 v/v, NovusBiological); polyclonal goat anti human kallistatin
(2 mL crude plasma, 1:2000 v/v, R&D systems); monoclonal mouse
anti human carboxypeptidase B2 (2 mL crude plasma, 1:1000 v/v,
Abcam); polyclonal goat anti human pleckstrin (25 mg depleted
plasma, 1:1000 v/v, Abcam); polyclonal rabbit anti human CPN1
(25 mg depleted plasma, 1:500 v/v, Abcam); polyclonal rabbit anti
human CAP1 (25 mg depleted plasma, 1:500 v/v, Abcam);
monoclonal mouse anti human AMBP (10 mg depleted plasma,
1:500 v/v, Abnova); monoclonal mouse anti human vinculin (10 mg
depleted plasma, 1:100 v/v, Abcam); and monoclonal mouse anti
human serpin D1 (5 mg depleted plasma, 1:2000 v/v, Abcam).
Secondary antibodies, that were diluted 1:5000 v/v in 5% w/v
non fat dry milk in TBS-Tween and used at room temperature for
1.5 h, were: donkey anti goat (Abcam), ECL mouse IgG-HRP (GE
Healthcare), and ECL rabbit IgG-HRP (GE Healthcare). Finally,
the specific proteins were detected using ECL Plus Western
blotting detection reagent (GE Healthcare) followed by membrane
scanning with an Ettan DIGE Imager scanner (GE Healthcare) at
excitation/emission wavelengths of 480 nm/530 nm to yield
images with a pixel size of 100 mm.
Quantity One software (Biorad) was used for the acquisition of
intensity values of detected proteins from blot images. Normalized
(inter and intra membrane) intensity values were used to evaluate
differences between protein abundance levels in AAA compared to
control samples applying permutation test for nonparametric
inference (StatXact.8 software). Median values of normalized AAA
and control intensities were used to calculate AAA to control ratio
per membrane. For each protein, overall AAA to control ratio was
calculated as the mean value of AAA to control ratios per
membrane.
Supporting Information
Supporting Information S1 Quantitative MS analysis of
plasma proteins from AAA and control patients.
(DOC)
Supporting Information S2 Detailed aminoacid sequenc-
es of adiponectin and kallistatin. Sequences identified by
MS are indicated in blue. (A) There is not ‘‘K’’ or ‘‘R’’ in the signal
peptide sequence of adiponectin to allow identification by MS.
The first ‘‘K’’ or ‘‘R’’ in the sequence appears at position 33. (B)
There is not ‘‘K’’ or ‘‘R’’ in the signal peptide sequence of
kallistatin to allow identification by MS. The first ‘‘K’’ or ‘‘R’’ in
the sequence appears at position 50.
(TIF)
Supporting Information S3 Detailed aminoacid se-
quence of the proteolytic products of AMBP protein.
Alpha-1-microglobulin has a sequence of 183 aa, and MS
identification by PAcIFIC covered 57.9% of the sequence
AAA Plasma Biomarkers Detected by PAcIFIC MS
PLoS ONE | www.plosone.org 8 December 2011 | Volume 6 | Issue 12 | e28698(aminoacid indicated in blue) with 30.8% of the total spectral
counts corresponding to AMBP protein. Bikunin has a sequence of
147 aa, and MS identifications by PAcIFIC covered 61.2% of the
sequence (aminoacid indicated in blue) with 69.2% of the total
spectral counts corresponding to AMBP protein. 22 23 24 25 26
27 28 29 30 31 32 33 34 35.
(TIF)
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